Cambridge Cognition, a provider of cognitive assessment software for clinical trials, has secured several new contracts to support pharmaceutical clients with virtual clinical trials.
The company has seen increased interest in virtual or part-virtual assessments since Covid-19-driven lockdowns began as part of efforts to limit the spread of the virus. Pharmaceutical firms started seeking options to continue trials outside of the clinic.
The company received two contracts collectively valued at £1m ($1.2m) to support pharmaceutical firms in delivering clinical trials virtually.
Since its Cloud-based platform launch in 2017, Cambridge Cognition delivered over 50,000 assessments online, supporting virtual clinical trials.
As part of these efforts, Cambridge Cognition has re-designed several ongoing trials for its customers so that they can continue the completion of virtual assessments in patients’ homes rather than in clinics.
Cambridge Cognition CEO Matthew Stork said: “We are pleased to be able to offer virtual solutions for clinical trials to help drug development continue during this difficult time. There is a great interest being shown in moving to virtual trials and we expect this to be a fast growth segment of the market for years to come, even once the Covid-19 crisis has eased.
“During the pandemic, many businesses have learnt to adapt working practices. Virtual clinical trials have been considered for a long time, but the current crisis may be a catalyst towards change.
“The combination of our technological solutions for virtual trials, our regulatory compliant platforms, and experienced study management team have made us ideally placed to meet the evolving demands of the industry.”
In July last year, Cambridge Cognition announced its second commercial partnership with a pharmaceutical company for its NeuroVocalix platform.